Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial
出版年份 2020 全文链接
标题
Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial
作者
关键词
-
出版物
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 75, Issue 11, Pages 3379-3385
出版商
Oxford University Press (OUP)
发表日期
2020-07-09
DOI
10.1093/jac/dkaa334
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China
- (2020) Zunyou Wu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment
- (2020) Hossein Poustchi et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Emerging coronaviruses: Genome structure, replication, and pathogenesis
- (2020) Yu Chen et al. JOURNAL OF MEDICAL VIROLOGY
- Radiologic Management of COVID-19: Preliminary Experience of the Iranian Society of Radiology COVID-19 Consultant Group (ISRCC)
- (2020) Arash Mahdavi et al. Iranian Journal of Radiology
- Virological assessment of hospitalized patients with COVID-2019
- (2020) Roman Wölfel et al. NATURE
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
- (2020) Joshua Geleris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial
- (2020) Wei Tang et al. BMJ-British Medical Journal
- Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study
- (2020) Shufa Zheng et al. BMJ-British Medical Journal
- Viral dynamics in mild and severe cases of COVID-19
- (2020) Yang Liu et al. LANCET INFECTIOUS DISEASES
- Understanding COVID-19: what does viral RNA load really mean?
- (2020) Gavin M Joynt et al. LANCET INFECTIOUS DISEASES
- Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo
- (2019) Caroline S. de Freitas et al. PLoS Neglected Tropical Diseases
- Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child
- (2019) Jolien J. M. Freriksen et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication
- (2018) André C. Ferreira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study
- (2017) Mark S. Sulkowski et al. Hepatology International
- Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses
- (2017) Abdo A. Elfiky et al. JOURNAL OF MEDICAL VIROLOGY
- Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir
- (2015) Brian J. Kirby et al. CLINICAL PHARMACOKINETICS
- Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1
- (2014) Namiki Izumi et al. ANTIVIRAL THERAPY
- Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
- (2014) Christophe Hézode et al. GUT
- Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
- (2013) Eric Lawitz et al. LANCET INFECTIOUS DISEASES
- Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial
- (2012) Maribel Rodriguez-Torres et al. JOURNAL OF HEPATOLOGY
- Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
- (2012) Stanislas Pol et al. LANCET INFECTIOUS DISEASES
- Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
- (2011) Richard E. Nettles et al. HEPATOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started